VANCOUVER, BC and SAN DIEGO, CA, Sept. 21 /PRNewswire-FirstCall/ -- MIGENIX Inc. (formerly Micrologix Biotech Inc.) (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, will start trading on the TSX under the symbol "MGI" effective at the open on September 21, 2004. This change in trading symbol reflects the name change that was effective September 9, 2004. Trading on the US OTC market will be under the symbol "MGIFF" (formerly "MGIXF").
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. With its expertise and experience in product development, the Company is focused on advancing its clinical and preclinical stage pipeline of product candidates in the areas of infectious and degenerative diseases. MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.mbiotech.com/.
"Jim DeMesa" ----------------------- James DeMesa, M.D., MBA President & CEO Contacts: Jonathan Burke MIGENIX Inc. Tel: (604) 221-9666 Extension 241 jburke@mbiotech.com Gino de Jesus or Dian Griesel, Ph.D. The Investor Relations Group Tel: (212) 825-3210 Theproteam@aol.com
The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
MIGENIX Inc.CONTACT: Jonathan Burke, MIGENIX Inc., Tel: (604) 221-9666 Extension241, jburke@mbiotech.com; Gino de Jesus or Dian Griesel, Ph.D., TheInvestor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com;To request a free copy of this organization's annual report, please go tohttp://www.newswire.ca/ and click on reports@cnw.